Competitive and silent antagonism of recombinant 5-HT1B receptors by amiloride

Gen Pharmacol. 1997 Nov;29(5):749-51. doi: 10.1016/s0306-3623(97)00008-6.

Abstract

1. The cyclic adenosine monophosphate (cAMP) response of the diuretic amiloride was compared with sumatriptan at recombinant human 5-HT1B (h5-HT1B) receptor sites in stably transfected Chinese hamster ovary (CHO-K1) cells. 2. Amiloride, free of intrinsic activity (pEC50 < 3.0), competitively antagonized the sumatriptan-mediated inhibition (pEC50: 7.37) of 100 microM forskolin-induced cAMP formation with a pA2 value of 4.46. 3. The antagonist feature was not shared by the amiloride derivative ethylisopropylamiloride, notwithstanding a slightly higher 5-HT1B receptor-binding affinity (pKi: 4.87) than that of amiloride (pKi: 4.70).

Publication types

  • Comparative Study

MeSH terms

  • Amiloride / pharmacology*
  • Animals
  • Binding, Competitive / drug effects
  • CHO Cells
  • Colforsin / pharmacology
  • Cricetinae
  • Cyclic AMP / biosynthesis
  • Diuretics / pharmacology*
  • Guinea Pigs
  • Receptors, Serotonin / drug effects*
  • Serotonin Antagonists / pharmacology*
  • Sumatriptan / pharmacology

Substances

  • Diuretics
  • Receptors, Serotonin
  • Serotonin Antagonists
  • Colforsin
  • Amiloride
  • Sumatriptan
  • Cyclic AMP